ORIC Pharmaceuticals (ORIC) Stock Forecast, Price Target & Predictions
ORIC Stock Forecast
ORIC Pharmaceuticals stock forecast is as follows: an average price target of $17.00 (represents a 76.90% upside from ORIC’s last price of $9.61) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
ORIC Price Target
The average price target for ORIC Pharmaceuticals (ORIC) is $17.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $21.00 to $7.00. This represents a potential 76.90% upside from ORIC's last price of $9.61.
ORIC Analyst Ratings
According to 5 Wall Street analysts, ORIC Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ORIC stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ORIC Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 05, 2024 | Bradley Canino | Stifel Nicolaus | $20.00 | $9.48 | 110.97% | 108.12% |
| Mar 21, 2024 | Robert Burns | H.C. Wainwright | $21.00 | $14.59 | 43.93% | 118.52% |
| Mar 12, 2024 | David Nierengarten | Wedbush | $20.00 | $14.63 | 36.71% | 108.12% |
| Mar 12, 2024 | Matthew Biegler | Oppenheimer | $17.00 | $14.32 | 18.72% | 76.90% |
| Apr 05, 2022 | Yigel Nochomovitz | Citigroup | $7.00 | $6.90 | 1.45% | -27.16% |
The latest ORIC Pharmaceuticals stock forecast, released on Sep 05, 2024 by Bradley Canino from Stifel Nicolaus, set a price target of $20.00, which represents a 110.97% increase from the stock price at the time of the forecast ($9.48), and a 108.12% increase from ORIC last price ($9.61).
ORIC Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 4 |
| Avg Price Target | $20.00 | $20.00 | $19.50 |
| Last Closing Price | $9.61 | $9.61 | $9.61 |
| Upside/Downside | 108.12% | 108.12% | 102.91% |
In the current month, the average price target of ORIC Pharmaceuticals stock is $20.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 108.12% increase as opposed to ORIC Pharmaceuticals's last price of $9.61. This month's average price target is down 0.00% compared to last quarter, and up 2.56% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 10, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 07, 2024 | Citigroup | Buy | Buy | Hold |
| Mar 21, 2024 | Needham | Buy | Buy | Hold |
| Mar 12, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Mar 23, 2023 | H.C. Wainwright | - | Buy | Upgrade |
| Mar 21, 2023 | Guggenheim | - | Buy | Upgrade |
| Mar 16, 2023 | Oppenheimer | - | Outperform | Upgrade |
| May 16, 2022 | Needham | Buy | Buy | Hold |
ORIC Pharmaceuticals's last stock rating was published by Oppenheimer on Jul 10, 2024. The company gave ORIC a "Outperform" rating, the same as its previous rate.
ORIC Pharmaceuticals Financial Forecast
ORIC Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
ORIC Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ORIC's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
ORIC Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict ORIC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ORIC Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
ORIC Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-37.28M | $-36.35M | $-36.82M | $-35.88M | $-35.25M | $-34.19M | $-29.02M |
| High Forecast | $-37.28M | $-36.35M | $-36.82M | $-35.88M | $-35.25M | $-31.28M | $-29.02M |
| Low Forecast | $-37.28M | $-36.35M | $-36.82M | $-35.88M | $-35.25M | $-37.83M | $-29.02M |
| Surprise % | - | - | - | - | - | - | - |
ORIC Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ORIC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
ORIC Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
ORIC Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ORIC last annual SG&A of $NaN (undefined).
ORIC Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.53 | $-0.52 | $-0.52 | $-0.51 | $-0.50 | $-0.49 | $-0.41 |
| High Forecast | $-0.53 | $-0.52 | $-0.52 | $-0.51 | $-0.50 | $-0.44 | $-0.41 |
| Low Forecast | $-0.53 | $-0.52 | $-0.52 | $-0.51 | $-0.50 | $-0.54 | $-0.41 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, ORIC Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ORIC previous annual EPS of $NaN (undefined).
ORIC Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.50 | $24.75 | 1550.00% | Buy |
| IMRX | Immuneering | $1.18 | $17.50 | 1383.05% | Buy |
| ANTX | AN2 Therapeutics | $1.02 | $8.75 | 757.84% | Buy |
| HOWL | Werewolf Therapeutics | $2.02 | $12.00 | 494.06% | Buy |
| MOLN | Molecular Partners | $5.51 | $29.00 | 426.32% | Buy |
| PEPG | PepGen | $8.83 | $29.50 | 234.09% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.80 | $6.00 | 233.33% | Buy |
| EWTX | Edgewise Therapeutics | $17.52 | $48.00 | 173.97% | Buy |
| MLYS | Mineralys Therapeutics | $11.23 | $30.00 | 167.14% | Buy |
| CCCC | C4 Therapeutics | $5.40 | $11.33 | 109.81% | Hold |
| CELC | Celcuity | $15.06 | $31.50 | 109.16% | Buy |
| PHVS | Pharvaris | $19.12 | $38.50 | 101.36% | Buy |
| CGEM | Cullinan Oncology | $17.98 | $32.00 | 77.98% | Buy |
| ORIC | ORIC Pharmaceuticals | $9.65 | $17.00 | 76.17% | Buy |
| ELVN | Enliven Therapeutics | $21.44 | $33.00 | 53.92% | Buy |
ORIC Forecast FAQ
Is ORIC Pharmaceuticals a good buy?
Yes, according to 5 Wall Street analysts, ORIC Pharmaceuticals (ORIC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of ORIC's total ratings.
What is ORIC's price target?
ORIC Pharmaceuticals (ORIC) average price target is $17 with a range of $7 to $21, implying a 76.90% from its last price of $9.61. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will ORIC Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for ORIC stock, the company can go up by 76.90% (from the last price of $9.61 to the average price target of $17), up by 118.52% based on the highest stock price target, and down by -27.16% based on the lowest stock price target.
Can ORIC Pharmaceuticals stock reach $14?
ORIC's average twelve months analyst stock price target of $17 supports the claim that ORIC Pharmaceuticals can reach $14 in the near future.
What is ORIC Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $20 price target for ORIC Pharmaceuticals (ORIC) this month, up 108.12% from its last price of $9.61. Compared to the last 3 and 12 months, the average price target increased by 108.12% and increased by 102.91%, respectively.
What are ORIC Pharmaceuticals's analysts' financial forecasts?
ORIC Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-98.455M (high $-95.544M, low $-102M), average SG&A $0 (high $0, low $0), and average EPS is $-1.4 (high $-1.358, low $-1.451). ORIC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-146M (high $-146M, low $-146M), average SG&A $0 (high $0, low $0), and average EPS is $-2.08 (high $-2.08, low $-2.08).